Navigation Links
Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
Date:10/2/2009

MOUNTAIN VIEW, Calif., Oct. 2 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that company management will present a corporate overview during the Fourth Annual JMP Securities Healthcare Focus Conference, being conducted at the New York Palace Hotel in New York. This corporate overview will be webcast live on Tuesday, October 6, 2009 at 10:30 a.m. Eastern Time.

To access the live presentation via the Web, please go to the direct conference link located at www.wsw.com/webcast/jmp9/alxa/ or at the Alexza Investor Relations tab at www.alexza.com.

A replay of the Webcast will be made available approximately 24 hours after the live presentation and the replay will be archived for 14 days.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting a New Drug Application submission in early 2010.

Alexza has completed an
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
2. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
3. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
4. Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
5. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
6. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
7. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
8. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
9. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
10. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
11. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 BioCorRx, Inc. ( ... Santa Ana, California is a healthcare solutions organization, ... is estimated at $22 billion in the U.S. alone. The ... of FDA-approved Naltrexone in a specially compounded form for outpatient ... Australia and New Zealand ) ...
(Date:3/27/2015)... -- Object recognition technology has a unique and powerful ... VelaSense ® mobile platform incorporates applications ... and fulfilling lives. VelaSense ® will now incorporate ... objects from a one million object database, that is ... for personal use. Visus Technology ...
(Date:3/27/2015)... -- Biopharmaceutical Industry Leads Manufacturing Sector in R&D ... top as the country,s manufacturing leader in innovation and ... According to the  analysis , the industry had the ... decade, accounting for 27 percent of average annual R&D ... Video on Medicare Part D - Medicare Part ...
Breaking Medicine Technology:Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2VelaSense Object Recognition Technology for the Blind was unveiled at Baruch College's CCVIP 8th Annual Conference 2Week in Review: The Latest from PhRMA 2
... Analyses of School and Daycare Study Outcomes ... for,Community at Large, TORONTO, May 08, 2007 ... showing that use of FluMist(R),(Influenza Virus Vaccine ... help reduce the burden of seasonal influenza. ...
... - Regeneron,Pharmaceuticals, Inc. (Nasdaq: REGN) today announced positive,results ... the,neovascular form of age-related macular degeneration (wet AMD) ... this,week at the annual meeting of the Association ... reported at the meeting,from a pre-planned interim analysis ...
Cached Medicine Technology:Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 2Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 3Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 4Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 5Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 6Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 7Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 8VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting 2VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting 3VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting 4VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting 5
(Date:3/28/2015)... (PRWEB) March 28, 2015 With ... in the fields of osteoporosis, osteoarthritis and musculoskeletal ... Osteoporosis, it may be the first time in ... research forum that the hot-button topic is an ... on the well-accepted scientific principles of Wolff’s law, ...
(Date:3/28/2015)... The California-based leading wig brand UniWigs has prepared a ... during the Easter Holidays from today until April 6th. ... Fools’ Day. , As the winter fades and spring ... Festival, with religious origins to countries in Europe and ... The best wig provider, UniWigs, would like to offer ...
(Date:3/28/2015)... 28, 2015 India Network visitor ... made available to all visitors who purchase the plan ... members are encouraged to purchase the insurance program as ... of proper coverage for pre-existing medical conditions. Parents and ... two medical conditions with serious consequences to their health. ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Centurion Service Group ... auction on Thursday, April 2 at their Las Vegas warehouse, ... NV 89081. The sale, which consists of equipment from hospitals ... promptly at 9 a.m. PDT. , Buyers will find ... surgery equipment. “We are a one-stop-shop,” said Erik Tivin, CEO ...
(Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 ... experiences re-injury, according to research presented today at the ... Specialty Day. The study examined the long term success ... , “We examined survey data from 242 patients ... lead author Justin P. Roe, MBBS, FRACS, from North ...
Breaking Medicine News(10 mins):Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Medical Equipment Auction to Take Place in North Las Vegas 2Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2
... the world sparking many lifestyle ailments like type 2 diabetes, ... ordered. A pill// is soon gaining ground for preventing type ... the pill once or twice daily, enhances the body’s receptive ... diabetes. ,The pill, named as rosiglitazone, marketed ...
... of the European Association for the Study of Diabetes ... antidiabetic medication, demonstrated significant cardiovascular benefits such as reducing ... coronary syndrome in patients with type 2 diabetes. ... premature death in patients with diabetes. An estimated 171 ...
... during cataract surgery have led to a new—and controversial—surgical ... farsightedness that typically develops in middle age. But a ... this operation to weigh its risks, as well as ... lenses, which enable people to see objects at varying ...
... Medicine (ABIM)and the American Society of Hematology (ASHTM) ... evaluation tools for// blood specialists. ... Improvement Module (PIM), which is a web-based tool ... requirement for recertification for ABIM. Participants in ABIM's ...
... 1199NW has said that it supports the "Marty Smith" ... a partner when// they visit high-risk patients. Marty Smith ... of Larry Clark, a child rapist whose mother had ... his medications. ,Smith's case proves that mental ...
... and and Amylin Pharmaceuticals has announced that exenatide is ... iphasic insulin // aspart 30/70 (NovoMix by NovoNordisk). This finding ... This is indeed a boon to people suffering type 2 ... oral diabetes drugs. , ,The study, which ...
Cached Medicine News:Health News:ACTOS Linked to Several Cardiovascular Benefits 2Health News:ACTOS Linked to Several Cardiovascular Benefits 3Health News:ACTOS Linked to Several Cardiovascular Benefits 4Health News:Improved Patient Care from Blood Specialists with New Web based Tool 2
... style offers men and women updated shapes and ... feature modern shapes and easy to wear deigns ... a casual look with combinations of metal fronts ... custom Hush Puppies nosepads for added comfort and ...
... name Silhouette stands for the power ... began in 1964 with just one ... a novel, pioneering approach: eyewear was ... implement to improve faulty vision; rather, ...
... Eyewear Collection reflects the ... elegance, refinement and comfort ... dedication to quality and ... of the Lacoste brand, ...
... Charmant's Pure Titanium Collection is the ... frames, consisting of 100% pure titanium ... hypoallergenic composition and superior corrosion resistance. ... and durability delivers a collection that ...
Medicine Products: